CO6640286A2 - Proceso in vitro para la determinacion rapida en un paciente del estado de infeccion con mycrobacterium tuberculosis - Google Patents

Proceso in vitro para la determinacion rapida en un paciente del estado de infeccion con mycrobacterium tuberculosis

Info

Publication number
CO6640286A2
CO6640286A2 CO12162307A CO12162307A CO6640286A2 CO 6640286 A2 CO6640286 A2 CO 6640286A2 CO 12162307 A CO12162307 A CO 12162307A CO 12162307 A CO12162307 A CO 12162307A CO 6640286 A2 CO6640286 A2 CO 6640286A2
Authority
CO
Colombia
Prior art keywords
infection
tuberculosis
cells
rapid determination
status
Prior art date
Application number
CO12162307A
Other languages
English (en)
Inventor
Ferdinand Hermann Bahlmann
Danilo Fliser
Martina Sester
Urban Sester
Original Assignee
Red Flag Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Flag Diagnostics Gmbh filed Critical Red Flag Diagnostics Gmbh
Publication of CO6640286A2 publication Critical patent/CO6640286A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un proceso in-vitro para la determinación rápida del estado de infección de una infección por Mycobacterium tuberculosis a partir de sangre completa en términos de una tuberculosis activa o latente, que comprende los pasos de:• estimular una célula T especifica del antígeno presente en una primera muestra de sangre completa con derivado de proteínas purificado (PPD) en la presencia de anticuerpos contra CD28 o CD28 y CD49d;• Procesar el PPD por células presentadoras de antígenos (APC) por incubación durante 1,5 h a 2,5 h, en especial durante 2h, a 35°C - 39°C, en especial a 37°C, opcionalmente con adición de CO;• Luego agregar un inhibidor de la secreción;• realizar un mezclado exhaustivo; y• incubar adicionalmente por un periodo da al manos 2,5 h a una temperatura de entre 35°C y 39°C, y• determinar el perfil de citoquinas a partir de le producción de INF-? intracelular y la producción de IL-2 intracelular de la célula T específica del antígeno; en donde• la presencia de una tuberculosis activa está indicada por un cambio en el perfil de citoquinas para células IFN-? simples positivas acompañado por una disminución de células T IFN-?/IL-2 positivas dobles.
CO12162307A 2010-03-19 2012-09-19 Proceso in vitro para la determinacion rapida en un paciente del estado de infeccion con mycrobacterium tuberculosis CO6640286A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28270110P 2010-03-19 2010-03-19
EP10157086 2010-03-19

Publications (1)

Publication Number Publication Date
CO6640286A2 true CO6640286A2 (es) 2013-03-22

Family

ID=42457988

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12162307A CO6640286A2 (es) 2010-03-19 2012-09-19 Proceso in vitro para la determinacion rapida en un paciente del estado de infeccion con mycrobacterium tuberculosis

Country Status (16)

Country Link
US (2) US20130122523A1 (es)
EP (1) EP2548019A1 (es)
JP (1) JP5925184B2 (es)
KR (1) KR20130029063A (es)
AU (1) AU2011228996B2 (es)
BR (1) BR112012023678A2 (es)
CA (1) CA2793151C (es)
CL (1) CL2012002542A1 (es)
CO (1) CO6640286A2 (es)
CU (1) CU20120141A7 (es)
MD (1) MD20120084A2 (es)
MX (1) MX2012010720A (es)
RU (1) RU2012144417A (es)
SG (1) SG184103A1 (es)
WO (1) WO2011113953A1 (es)
ZA (1) ZA201206950B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9146236B2 (en) 2010-12-23 2015-09-29 Giuseppe Pantaleo Methods for differentiating between disease states
WO2012167307A1 (en) * 2011-06-06 2012-12-13 The University Of Melbourne Diagnosis of mycobacterial infection
WO2013106338A1 (en) 2012-01-12 2013-07-18 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
GB201315748D0 (en) 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
JP6306124B2 (ja) * 2016-11-01 2018-04-04 国立大学法人高知大学 結核検査用バイオマーカー
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CN107831316A (zh) * 2017-10-31 2018-03-23 扬州大学 一种用于诊断牛结核病的流式细胞术检测试剂盒
CN109777852A (zh) * 2019-01-29 2019-05-21 浙江省人民医院 特异性抗原刺激cd4淋巴细胞表达cd69用于诊断结核杆菌感染的方法
KR102326294B1 (ko) * 2019-10-27 2021-11-16 바디텍메드(주) 결핵 진단 장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US7135280B2 (en) * 2001-01-08 2006-11-14 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
WO2006069460A2 (de) * 2004-12-30 2006-07-06 Medmix Systems Ag Mehrkomponenten-austragvorrichtung für flüssige und pulverförmige stoffe
NZ560468A (en) * 2005-01-05 2010-05-28 Isis Innovation Compositions for immunizing against mycobacterium using Ag85A
EP1767937A1 (en) * 2005-09-27 2007-03-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of diagnosis of tuberculosis related immune restoration syndrome (IRS)
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
ES2558543T3 (es) 2007-03-16 2016-02-05 Cellestis Limited Un ensayo de respuesta inmunitaria mediada por células y kits para el mismo

Also Published As

Publication number Publication date
KR20130029063A (ko) 2013-03-21
US20150099652A1 (en) 2015-04-09
MD20120084A2 (ro) 2013-04-30
BR112012023678A2 (pt) 2016-08-23
US20130122523A1 (en) 2013-05-16
ZA201206950B (en) 2013-05-29
AU2011228996B2 (en) 2015-01-29
SG184103A1 (en) 2012-10-30
MX2012010720A (es) 2013-01-29
CL2012002542A1 (es) 2013-02-08
AU2011228996A1 (en) 2012-10-11
CA2793151A1 (en) 2011-09-22
CA2793151C (en) 2018-05-22
JP2013522637A (ja) 2013-06-13
EP2548019A1 (en) 2013-01-23
WO2011113953A1 (en) 2011-09-22
JP5925184B2 (ja) 2016-05-25
RU2012144417A (ru) 2014-04-27
CU20120141A7 (es) 2013-01-30
US9476877B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
CO6640286A2 (es) Proceso in vitro para la determinacion rapida en un paciente del estado de infeccion con mycrobacterium tuberculosis
Smith et al. Intracellular cytokine staining and flow cytometry: considerations for application in clinical trials of novel tuberculosis vaccines
ES2538817T3 (es) Método para la inducción simultánea de CTL y células gamma delta T
ES2559763T3 (es) Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
BR112016007547A2 (pt) ?vetor de expressão bicistrônico para expressão de anticorpos e método para a produção de anticorpos usando o mesmo?
PE20191324A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
WO2007044418A3 (en) Cell culture media, kits and methods of use
Boer et al. CD8+ regulatory T cells, and not CD4+ T cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cells
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
FR3020379B1 (fr) Procede de production de methane par co-culture aerobie de microorganismes anaerobies
WO2007146811A3 (en) Assessment of cellular composition and fractional viability and uses thereof
BR112016018826A8 (pt) anticorpo purificado, ou fragmento de ligação de antígeno, método para a identificação de uma população de células de esperma de mamífero portadoras de cromossomo x, e método in vitro para distorcer uma proporção entre os sexos
PL415351A1 (pl) Sposób namnażania in vitro komórek T regulatorowych (Treg)
EP4150059A4 (en) ANTIGEN-PRESENTING T CELLS, MANUFACTURED SENSITIZED T CELLS, AND METHODS OF TREATMENT USING THEM
RU2009119959A (ru) Способ получения сыворотки для диагностики коксиеллеза крупного рогатого скота в реакции непрямой иммунофлуоресценции путем гипериммунизации кроликов
MX2021014201A (es) Métodos relacionados con la tuberculosis.
Pedersen et al. Development of assay platforms for in vitro screening of Treg modulating potential of pharmacological compounds
Yavasoglu et al. Penile ulcer ATRA related in patient with acute promyelocytic leukemia
Üreyen et al. Fournier gangrenli hastalarda mortalite tahmininde FGSİ ve UFGSİ skorlama sistemlerinin prediktif değeri: Çok merkezli çalışma
Jintao Paradox Strategy of Plaths “Confessional” Poetry
NO20072633L (no) Kjemisk prosess
Cikirikcioglu et al. Mitral annuloplasty using an intra-annular ring.
TR202101567U5 (tr) Tekerlekli̇ sandalyeler i̇çi̇n bi̇r çeki̇ci̇
Jaya et al. Measurement of elastin expression after in vitro application of potassium channel openers in RFL6 cells
Hansen et al. The localization of glutamate-cystine exchanger xCT (slc7a11) in mouse brain